NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP
Lexaria Bioscience Corp. LEXX
14 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$705,923
▲ 52.0% vs FY2024
EPS · FY25
$-0.66
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-215.9%
Net margin · FY25
-1686.0%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 705,923.00
Revenue, FY2025 · full 14-year series below
Revenue
Net income
The company lost 1686 cents on every revenue dollar this year.
Per share
USD -0.66
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
-215.9%
Return on equity, FY2025
ROE
Operating margin-1683.0%
Net margin-1686.0%
Return on assets-182.5%
Each USD of equity lost 216 cents this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
+17.5% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+40.3%
+17.5%
+47.3%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.02B
Shares outstanding, FY2025
Change, 5 years+130.0%
Change, 10 years—
The share count grew 130% in five years — the same company, cut into more, smaller slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 4.2M
total assets, end of FY2025
Total assetsUSD 4.2M
EquityUSD 3.0M
CashUSD 1.8M
Current ratio2.32×
Equity funds 72% of total assets.
History
14 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2011
2010
Revenue $B
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
·
·
Operating income $B
−0.0
−0.0
−0.0
−0.0
−0.0
·
·
·
·
−0.0
−0.0
−0.0
·
·
EBITDA $B
−0.0
−0.0
·
·
−0.0
·
·
·
·
−0.0
−0.0
·
·
·
Income tax $B
·
·
·
0.0
0.0
0.0
0.0
0.0
0.0
0.0
·
·
·
·
Net income $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EPS, diluted $
−0.66
−0.47
−1.01
·
−0.95
−1.47
−0.05
−0.09
−0.03
−0.03
−0.04
−0.14
−0.04
−0.04
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
·
·
·
ROE %
−215.9
−104.6
−121.3
−68.5
−51.1
−164.3
−170.5
−256.4
−127.2
−246.0
−142.2
−81.7
−22.4
−25.7
Shares out B
0.02
0.02
0.01
0.01
0.01
0.00
0.08
0.08
0.07
0.05
0.04
0.03
0.02
0.01
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
56 of 57
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 1 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed